Hill-Rom Holdings, Inc. (NYSE:HRC) has earned an average recommendation of “Hold” from the eleven analysts that are covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $95.17.

Several brokerages recently issued reports on HRC. Zacks Investment Research upgraded Hill-Rom from a “sell” rating to a “hold” rating in a report on Monday, September 18th. ValuEngine lowered Hill-Rom from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Raymond James Financial upgraded Hill-Rom from a “market perform” rating to an “outperform” rating and set a $94.00 price objective for the company in a report on Wednesday, January 3rd. Barclays increased their price objective on Hill-Rom from $86.00 to $90.00 and gave the stock an “overweight” rating in a report on Monday, November 6th. Finally, Bank of America reiterated a “hold” rating on shares of Hill-Rom in a report on Wednesday, November 22nd.

Shares of Hill-Rom (HRC) opened at $86.79 on Tuesday. The stock has a market capitalization of $5,712.60, a price-to-earnings ratio of 43.61, a PEG ratio of 1.55 and a beta of 1.19. Hill-Rom has a 1-year low of $57.18 and a 1-year high of $88.91. The company has a quick ratio of 1.34, a current ratio of 1.77 and a debt-to-equity ratio of 1.55.

Hill-Rom (NYSE:HRC) last released its earnings results on Friday, November 3rd. The medical technology company reported $1.32 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.27 by $0.05. The company had revenue of $738.30 million during the quarter, compared to analyst estimates of $731.10 million. Hill-Rom had a return on equity of 20.27% and a net margin of 4.87%. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.18 earnings per share. sell-side analysts expect that Hill-Rom will post 4.32 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Friday, December 29th. Shareholders of record on Friday, December 15th were issued a dividend of $0.18 per share. The ex-dividend date was Thursday, December 14th. This represents a $0.72 annualized dividend and a yield of 0.83%. Hill-Rom’s dividend payout ratio (DPR) is currently 36.18%.

In other Hill-Rom news, CEO John J. Greisch sold 125,241 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $82.59, for a total transaction of $10,343,654.19. Following the transaction, the chief executive officer now directly owns 280,851 shares in the company, valued at $23,195,484.09. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Paul Sherwood Johnson sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $82.99, for a total value of $82,990.00. Following the transaction, the senior vice president now owns 1,066 shares in the company, valued at $88,467.34. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 226,241 shares of company stock worth $18,708,644. Corporate insiders own 2.20% of the company’s stock.

Several large investors have recently modified their holdings of the company. Stifel Financial Corp grew its position in shares of Hill-Rom by 0.5% in the second quarter. Stifel Financial Corp now owns 4,379 shares of the medical technology company’s stock valued at $349,000 after purchasing an additional 23 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Hill-Rom by 10.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,201 shares of the medical technology company’s stock valued at $175,000 after purchasing an additional 204 shares during the last quarter. ETRADE Capital Management LLC grew its position in shares of Hill-Rom by 4.6% in the second quarter. ETRADE Capital Management LLC now owns 6,940 shares of the medical technology company’s stock valued at $552,000 after purchasing an additional 303 shares during the last quarter. Ameritas Investment Partners Inc. grew its position in shares of Hill-Rom by 2.2% in the second quarter. Ameritas Investment Partners Inc. now owns 17,910 shares of the medical technology company’s stock valued at $1,426,000 after purchasing an additional 378 shares during the last quarter. Finally, Citigroup Inc. grew its position in shares of Hill-Rom by 21.1% in the second quarter. Citigroup Inc. now owns 2,483 shares of the medical technology company’s stock valued at $198,000 after purchasing an additional 433 shares during the last quarter. 81.92% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/01/16/hill-rom-holdings-inc-hrc-given-consensus-rating-of-hold-by-brokerages.html.

Hill-Rom Company Profile

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

Analyst Recommendations for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.